Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
58 hedge funds and large institutions have $185M invested in Dicerna Pharmaceuticals, Inc. in 2015 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 18 reducing their positions, and 4 closing their positions.
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
44% more capital invested
Capital invested by funds: $128M → $185M (+$56.4M)
14% more funds holding
Funds holding: 51 → 58 (+7)
6% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 18
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.89M |
| 2 |
OPPM
Opus Point Partners Management
New York
|
+$1.14M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$706K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$690K |
| 5 |
California Public Employees Retirement System
Sacramento,
California
|
+$469K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.01M |
| 2 |
Morgan Stanley
New York
|
-$1.36M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.08M |
| 4 |
IHM
Iguana Healthcare Management
New York
|
-$821K |
| 5 |
AIC
AWM Investment Company
New York
|
-$657K |
DRNA Hedge Fund Activity: Q4 2015 in Review
58 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q4 2015, worth a combined $185M — up 44% from $128M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new DRNA positions and 4 closed out — a net gain of 7 holders — while 19 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $2.89M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $2.01M sold.
- 58 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q4 2015, up from 51 in Q3 2015.
- Funds reported $185M of Dicerna Pharmaceuticals, Inc. stock for Q4 2015, up 44% quarter-over-quarter.
- 11 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q4 2015 and 4 closed out, a net change of +7 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q4 2015 was BlackRock Fund Advisors, an estimated $2.89M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q4 2015 was Cormorant Asset Management, an estimated $2.01M sold.
Based on aggregated 13F filings for Q4 2015.